INTERNATIONAL FLAVORS & FRAGRANCES INC (IFF)
SEC filings, insider trading & institutional ownership from EDGAR.
IFF (International Flavors & Fragrances) is a leading creator and manufacturer of products for food, beverage, health and biosciences, and scent applications, along with complementary adjacent products such as natural health ingredients. Its products are used in a wide variety of consumer and end-use products, and the company holds global leadership positions in the Food & Beverage, Home & Personal Care and Health & Wellness markets. Sales in 2025 were $10.890 billion.
During 2025 the business had four continuing segments: Taste, Food Ingredients, Health & Biosciences and Scent. A fifth segment, Pharma Solutions, was part of the business until its divestiture in May 2025, together with the nitrocellulose disposal group. Effective January 1, 2025, the former Nourish segment was split into Taste and Food Ingredients. Taste develops flavor compounds and natural taste solutions for savory products, beverages, sweets and dairy, and includes spices and seasoning ingredients. Food Ingredients offers natural, artificial and plant-based specialty ingredients, including soy and pea proteins, emulsifiers, sweeteners, natural food protection ingredients, savory solutions and inclusion products. Health & Biosciences produces enzymes, food cultures, probiotics and specialty ingredients through its Health, Food Biosciences, Home & Personal Care, Animal Nutrition and Grain Processing units. Scent creates fragrance compounds for fine fragrance and consumer products (fabric care, home care and body care) and fragrance ingredients, which are used internally and sold to third parties, including competitors.
Customers are mainly manufacturers of dairy, meat, beverages, snacks, savory and sweet goods, baked goods, personal care products, soaps and detergents, cleaning products, perfumes, dietary supplements, infant, elderly and animal nutrition, functional food, biofuel and oral care products. Sales are geographically diverse: the U.S. accounted for about 28% of 2025 sales and no other country exceeded 10%. No customer represented 10% or more of sales. Some large customers limit their supplier lists through "core lists," and private label manufacturers are a growing customer segment.
IFF relies on research and development, with about 3,000 employees in R&D, 849 granted U.S. patents and principal R&D sites in Union Beach (NJ), Wilmington (DE), Palo Alto (CA), Brabrand (Denmark) and Leiden (The Netherlands). It sources about 20,000 raw materials, natural and synthetic, from domestic and international suppliers. It operates about 170 manufacturing facilities, creative centers and application laboratories in about 30 countries, and has roughly 21,500 employees. Its main competitors include Givaudan, Novonesis, DSM-Firmenich, Symrise, Kerry and ADM, as well as mid-sized, regional and local manufacturers and consumer product companies that develop their own products. Its operations are subject to food, chemical, environmental and workplace safety regulation. Principal executive offices are in New York, New York and Wilmington, Delaware.
AI-summarized from Item 1 (Business) of the company’s most recent 10-K filing.
Financials
As reported to the SEC via XBRL, no adjustments
| Gross profit | $3.94B |
| Operating income | -$382M |
| Diluted EPS | -$1.41 |
| Gross margin | 36.2% |
| Net margin | -3.3% |
Latest filings
10-K, 10-Q, 8-K, Form 4 & 13D/G. Sourced directly from SEC EDGAR
| Form | Filed | Accession |
|---|---|---|
| 10-Q | Nov 3, 2026 | 0000051253-26-000041EDGAR |
| 8-K | Nov 3, 2026 | 0000051253-26-000039EDGAR |
| 8-K | Nov 3, 2026 | 0001140361-26-041833EDGAR |
| 4Teles de Mendonca Ana Paula | Aug 19, 2026 | 0001225208-26-007193EDGAR |
| 4Birenkrant Marc | Aug 10, 2026 | 0001225208-26-007047EDGAR |
| 4DeVeau Michael | Aug 7, 2026 | 0001225208-26-007034EDGAR |
| 8-K | Aug 4, 2026 | 0000051253-26-000028EDGAR |
| 10-Q | Aug 4, 2026 | 0000051253-26-000030EDGAR |
Insider trading
From Form 4 filings
| Insider | Date | Type |
|---|---|---|
| Teles de Mendonca Ana Paula | Aug 17, 2026 | Sell |
| Birenkrant Marc | Aug 7, 2026 | Sell |
| DeVeau Michael | Aug 6, 2026 | Sell |
| FRIBOURG PAUL J | Jun 1, 2026 | Buy |
| FRIBOURG PAUL J | Jun 1, 2026 | Buy |
Top holders
13F & 13D/G • latest quarter
| Holder | Stake | Filed | Value |
|---|---|---|---|
| Dodge & Cox | 14.8% | Aug 13, 2026 | $2.93B |
| BlackRock, Inc. | 9.3% | Aug 7, 2026 | $1.84B |
| Vanguard Capital Management | 6.5% | Aug 13, 2026 | $1.29B |
| STATE STREET CORPORATION | 4.9% | Sep 22, 2026 | $982.39M |
| Vanguard Portfolio Management | 4.6% | Aug 13, 2026 | $919.64M |
IFF's filings are public. The insight is one click away.
Scrutar's AI reads every IFF filing and points out what matters. Red flags, risk shifts, disclosure quality and key relationships. Cited to the source, free with an account.
Never miss a IFF filing.
Get an email when IFF files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 8, 2026Source: SEC EDGAR.